STOCK TITAN

Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Cardiff Oncology (CRDF) reported a narrower third-quarter net loss while its Phase 2 colorectal cancer trial remained ongoing. Net loss was $8.857 million versus $11.258 million a year earlier; loss per share was $0.12 versus $0.17.

Median progression-free survival, or time without disease worsening, was not reached in the 30 mg onvansertib plus FOLFIRI/bevacizumab arm, versus approximately 11 months in the combined standard-of-care arms. Patients remaining in that onvansertib arm had received treatment for at least 21 months. Cardiff expects a Phase 3 start in Q1 2027, subject to additional financing.

Cash, cash equivalents and short-term investments totaled approximately $33.8 million at September 30. Cardiff expects these resources to fund operations through the end of Q3 2027. Nine-month operating cash use increased to approximately $33.9 million from $31.9 million.

Loading...
Loading translation...
14 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 10 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointJuly offering raised $10 million gross and approximately $9.1 million net. 17% of market cap
  • Moderate pointMedian progression-free survival was not reached in the 30 mg onvansertib/FOLFIRI/bevacizumab arm versus approximately 11 months in combined controls.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Phase 3 preparations target a Q1 2027 start, with vendor relationships and companion diagnostics being finalized.
  • Moderate pointGlobal onvansertib rights disputes with Nerviano Medical Sciences were resolved; the exclusive license agreement was amended in September.
  • Moderate pointQ3 net loss narrowed to $8.857 million from $11.258 million; loss per share narrowed to $0.12 from $0.17.
  • Moderate pointNine-month net loss narrowed to $30.434 million from $38.635 million; loss per share narrowed to $0.43 from $0.58.
8 minor points
  • Minor pointRemaining patients in the 30 mg onvansertib/FOLFIRI/bevacizumab arm reached at least 21 months on treatment; longest exceeded 29 months.
  • Minor pointFDA orphan drug designations granted for onvansertib in chronic myelomonocytic leukemia in October and small cell lung cancer in November.
  • Minor pointQ3 royalty revenue rose to $171,000 from $120,000 a year earlier.
  • Minor pointQ3 research and development expense fell to $5.029 million from $8.197 million a year earlier.
  • Minor pointQ3 operating loss narrowed to $9.219 million from $11.974 million a year earlier.
  • Minor pointNine-month research and development expense fell to $17.709 million from $30.254 million a year earlier.
  • Minor pointNine-month operating loss narrowed to $31.684 million from $41.133 million a year earlier.
  • Minor pointTotal liabilities fell to $8.316 million at September 30, 2026, from $16.496 million at December 31, 2025.

Negative

  • Major pointCommon stock and warrants issued in the July registered direct offering dilute existing holders.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Phase 3 initiation remains subject to securing additional financing.
  • Moderate pointNine-month operating cash use increased to approximately $33.9 million from $31.9 million a year earlier.
  • Moderate pointNine-month selling, general and administrative expense rose to $14.291 million from $11.229 million a year earlier.
  • Minor pointCash and cash equivalents fell to $12.060 million from $17.470 million at December 31, 2025.
5 minor points
  • Minor pointShort-term investments fell to $21.730 million from $40.834 million at December 31, 2025.
  • Minor pointQ3 selling, general and administrative expense rose to $4.361 million from $3.897 million a year earlier.
  • Minor pointNine-month royalty revenue declined to $316,000 from $350,000 a year earlier.
  • Minor pointInterest income fell to $363,000 from $716,000 in Q3 and $1.251 million from $2.492 million over nine months.
  • Minor pointStockholders’ equity declined to $28.098 million at September 30, 2026, from $45.388 million at December 31, 2025.

News Explained

In July, Cardiff completed a $10 million registered direct offering of common stock and warrants, receiving about $9.1 million net to support working capital and general corporate purposes; that common-stock issuance increases total shares and reduces existing holders’ percentage ownership, absent offsetting changes.

Argus Nov 12 session 3 alerts
-4.93% close to close 0.8x rel. volume Open Argus
Details

Market move: CRDF -4.93% in the Nov 12 session. 3Q26 earnings report

$56.81M Mkt Cap at Peak Alert

On Nov 12, the day this news came out, CRDF closed 4.93% below the previous close. Our momentum scanner recorded 3 alerts for this stock that day.

Data tracked by StockTitan Argus for the Nov 12 session.

Key Figures

Median PFS, 30 mg onvansertib arm: Not reached Median PFS, combined SoC arms: Approximately 11 months Treatment duration: At least 21 months +5 more
Median PFS, 30 mg onvansertib arm
Not reached
Onvansertib + FOLFIRI/bev arm
Median PFS, combined SoC arms
Approximately 11 months
Combined standard-of-care arms
Treatment duration
At least 21 months
Patients remaining in the 30 mg onvansertib + FOLFIRI/bev arm
Longest treatment duration
Over 29 months
30 mg onvansertib + FOLFIRI/bev arm
Expected Phase 3 initiation
Q1 2027
Subject to securing additional financing
Cash, cash equivalents, and short-term investments
Approximately $33.8 million
As of September 30, 2026
Net cash used in operating activities
Approximately $33.9 million
Nine months ended September 30, 2026
Cash runway
Through the end of Q3 2027
Company projection based on current expectations

Previous Earnings Reports

4 past events · Latest: May 14
Same Type 4 events
  1. May 14

    Earnings report

    24h Move
    -3.5%

    Reported Phase 2 data and selected the regimen for the planned first-line mCRC Phase 3 trial.

  2. Feb 24

    Earnings report

    24h Move
    +12.3%

    Reported 30 mg arm ORR and PFS results from the first-line mCRC Phase 2 trial.

  3. Nov 06

    Earnings report

    24h Move
    -2.7%

    Reported early ORR and PFS separation for onvansertib in the first-line mCRC Phase 2 trial.

  4. Jul 29

    Earnings report

    24h Move
    -24.8%

    Completed enrollment in the randomized Phase 2 trial evaluating onvansertib in first-line mCRC.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

progression-free survival, objective response rate, companion diagnostics, registered direct offering, +1 more
5 terms
progression-free survival medical
"Median progression-free survival (“PFS”) has not been reached"
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
objective response rate medical
"based on objective response rate and full approval based on PFS"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
companion diagnostics medical
"finalizing the companion diagnostics for RAS mutational status"
A companion diagnostic is a medical test used alongside a specific drug or therapy to identify which patients are likely to benefit from it or may face safety risks. Think of it as a tailored matchmaker that tells doctors whether a particular treatment is a good fit for an individual. For investors, these tests matter because they can shape a drug’s approved use, speed and cost of development, patient uptake, reimbursement, and the commercial value of both the therapy and the diagnostic.
registered direct offering financial
"completed a $10 million registered direct offering of common stock and warrants"
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
orphan drug designation regulatory
"FDA granted Orphan Drug Designation (“ODD”) to onvansertib"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms

All patients remaining in the 30 mg onvansertib + FOLFIRI/bev arm have now exceeded 21 months on treatment

Company preparing for registrational Phase 3 trial in first-line RAS-mutated mCRC, with potential start in Q1 2027

SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

“We’re greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combination with FOLFIRI/bev is becoming more evident, with growing separation between the onvansertib and control arms,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Building on the strength of these data, we are actively preparing for our upcoming registrational trial. There are currently no treatment options specifically approved for patients with pan-RAS-mutated mCRC in the first-line setting and we believe onvansertib has the potential to become an important new treatment for these patients.”

Clinical Highlights

Randomized Phase 2 Trial in First-Line RAS-Mutated Metastatic Colorectal Cancer (“mCRC”) Ongoing

Cardiff’s randomized Phase 2 trial evaluating onvansertib in combination with FOLFIRI/ bevacizumab (“bev”) or FOLFOX/bev as first-line therapy in patients with RAS-mutated mCRC remains ongoing. Median progression-free survival (“PFS”) has not been reached in the 30 mg onvansertib + FOLFIRI/bev arm, the Company’s proposed Phase 3 regimen.

As of September 28, 2026, 6 patients remain on the FOLFIRI/bev regimen, with 5 patients in the onvansertib (20 or 30 mg) + FOLFIRI/bev arms and 1 patient on standard-of-care (“SoC”) FOLFIRI/bev. Patients who remain in the 30 mg onvansertib + FOLFIRI/bev arm have been on treatment for at least 21 months, with the longest duration of treatment being over 29 months. For comparison, the median PFS in the combined SoC arms has been reached at approximately 11 months, consistent with what has been historically reported.

Preparing for the Registrational Phase 3 Trial in First-Line RAS-Mutated mCRC

Cardiff expects to initiate the Phase 3 trial in the first quarter of 2027, subject to securing additional financing. In preparation, the Company is establishing key vendor relationships for trial execution and clinical supply materials, as well as finalizing the companion diagnostics for RAS mutational status. The trial is designed to support potential accelerated approval based on objective response rate and full approval based on PFS.

Corporate Updates

  • In July, Cardiff completed a $10 million registered direct offering of common stock and warrants to support working capital and general corporate purposes. The full press release is available here.
  • In September, Cardiff and its licensor, Nerviano Medical Sciences S.r.l. (“NMS”), resolved all outstanding disputes regarding global rights to onvansertib and amended their 2017 exclusive license agreement. The full press release is available here.
  • In October, Cardiff appointed Leila Alland, MD, as interim Chief Medical Officer. Dr. Alland is a seasoned oncology executive who has served as Chief Medical Officer at several clinical-stage biotechnology companies and previously held leadership positions at AstraZeneca, Bristol Myers Squibb, Novartis and Schering-Plough, where she contributed to the development and approval of multiple oncology therapies. The full press release is available here.
  • In October, U.S. Food and Drug Administration (“FDA”) granted Orphan Drug Designation (“ODD”) to onvansertib for the treatment of patients with chronic myelomonocytic leukemia (“CMML”).
  • In November, FDA granted ODD to onvansertib for the treatment of patients with small cell lung cancer.

Upcoming Events

  • Cardiff management will present at the UBS Global Biopharma Conference and participate in one-on-one investor meetings on November 16–17, 2026. Dr. Mohindru’s presentation is scheduled for November 16 at 2:40 p.m. GMT. A live webcast and replay will be available in the “Events” section of the Cardiff Oncology website.
  • Updated data from an investigator-sponsored clinical trial in CMML will be presented at the American Society of Hematology (“ASH”) Annual Meeting on December 13, 2026.

Third Quarter 2026 Financial Results

Liquidity, cash burn, and cash runway

As of September 30, 2026, Cardiff Oncology had approximately $33.8 million in cash, cash equivalents, and short-term investments. Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $33.9 million, an increase of $2.0 million from $31.9 million for the same period in 2025. In July 2026, the Company raised net proceeds of approximately $9.1 million in a registered direct offering. Based on its current expectations and projections, the Company believes its current cash resources are sufficient to fund its operations to the end of the third quarter of 2027.

Operating results

Total operating expenses were approximately $32.0 million for the nine months ended September 30, 2026, a decrease of $9.5 million from $41.5 million for the same period in 2025. R&D expenses decreased by $12.5 million, reflecting the completion of clinical trials, fewer patients on treatment in the Phase 2 mCRC trial, a reduction in preclinical activities, and completion of chemistry, manufacturing and controls (“CMC”) activities as the Company prepares for its planned Phase 3 mCRC trial. SG&A expenses increased by $3.1 million, driven by legal and professional fees related to the Company’s dispute with NMS, which was resolved on September 14, 2026, and also by employee severance costs. Net loss was $30.4 million, compared with $38.6 million for the prior year period.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company targeting RAS-mutated cancers via innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially.

There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, uncertainties associated with clinical development and regulatory approvals; the possibility that results from earlier clinical studies may not be predictive of future results; risks related to the timing, initiation, conduct and completion of clinical trials; the Company's need for additional financing; dependence on key personnel and third parties; competition; intellectual property risks; and other factors described in Cardiff Oncology's filings with the Securities and Exchange Commission. There can be no assurance that onvansertib will receive regulatory approval for any indication or prove commercially successful.

Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Investor Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

Cardiff Oncology, Inc.
Condensed Statements of Operations
(in thousands, except for per share amounts)
(unaudited)
       
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
 
  2026   2025  2026   2025 
Royalty revenues $171   $120  $316   $350 
Costs and expenses:            
Research and development  5,029    8,197   17,709    30,254 
Selling, general and administrative  4,361    3,897   14,291    11,229 
Total operating expenses  9,390    12,094   32,000    41,483 
             
Loss from operations  (9,219)    (11,974)   (31,684)    (41,133) 
             
Other income (expense), net:            
Interest income  363    716   1,251    2,492 
Other income (expense), net  (1)    —   (1)    6 
Total other income (expense), net  362    716   1,250    2,498 
             
Net loss  (8,857)    (11,258)   (30,434)    (38,635) 
             
Preferred stock dividend  (6)    (6)   (18)    (18) 
             
Net loss attributable to common stockholders $(8,863)   $(11,264)  $(30,452)   $(38,653) 
             
Net loss per common share — basic and diluted $(0.12)   $(0.17)  $(0.43)   $(0.58) 
             
Weighted-average shares outstanding — basic and diluted  76,178    66,879   71,004    66,644 


Cardiff Oncology, Inc.
Condensed Balance Sheets
(in thousands)
(unaudited)
         
         
  September 30,
2026
  December 31,
2025
 
Assets      
Current assets:      
Cash and cash equivalents $12,060  $17,470 
Short-term investments  21,730   40,834 
Accounts receivable and unbilled receivable  90   182 
Prepaid expenses and other current assets  1,146   1,642 
Total current assets  35,026   60,128 
Property and equipment, net  364   578 
Operating lease right-of-use assets  225   629 
Other assets  799   549 
Total Assets $36,414  $61,884 
       
Liabilities and Stockholders’ Equity      
Current liabilities:      
Accounts payable $693  $8,087 
Accrued liabilities  7,358   7,577 
Operating lease liabilities  265   730 
Total current liabilities  8,316   16,394 
Operating lease liabilities, net of current portion  —   102 
Total Liabilities  8,316   16,496 
       
Stockholders’ equity  28,098   45,388 
Total liabilities and stockholders’ equity $36,414  $61,884 



FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cardiff Oncology's Phase 2 colorectal cancer trial show?

Median progression-free survival was not reached in the 30 mg onvansertib plus FOLFIRI/bevacizumab arm, compared with approximately 11 months in the combined standard-of-care arms. Patients remaining in that onvansertib arm had been treated for at least 21 months, with the longest treatment duration exceeding 29 months.

When does Cardiff Oncology expect to start its Phase 3 trial?

Cardiff expects to initiate its first-line RAS-mutated metastatic colorectal cancer Phase 3 trial in the first quarter of 2027, subject to securing additional financing. The trial is designed to support potential accelerated approval based on objective response rate, which measures tumor responses, and full approval based on progression-free survival.

Why did Cardiff Oncology's research and development expenses decline?

The nine-month decline reflected completed clinical trials, fewer patients on treatment in the Phase 2 colorectal cancer trial, reduced preclinical activities and completed chemistry, manufacturing and controls activities. Research and development expense was $17.709 million for the nine months ended September 30, 2026, versus $30.254 million a year earlier.

When will Cardiff Oncology present updated chronic myelomonocytic leukemia trial data?

Updated data from an investigator-sponsored trial in chronic myelomonocytic leukemia will be presented at the American Society of Hematology Annual Meeting on December 13, 2026.

Keep reading